Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M.
Takada M, et al. Among authors: hozumi y.
Breast Cancer Res Treat. 2014 May;145(1):143-53. doi: 10.1007/s10549-014-2907-9. Epub 2014 Mar 30.
Breast Cancer Res Treat. 2014.
PMID: 24682674
Free article.